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R e c o m m e n d e db yD a v i dF .P e n s o n
Penile rehabilitation therapy following radical prostatectomy is a much debated topic. Erectile dysfunction is still a signiﬁcant
contributor to postoperative morbidity following radical prostatectomy, despite meticulous nerve-sparing technique. Secondary
smooth muscle changes in the penis have been identiﬁed as the underlying causes of penile atrophy, veno-occlusive dysfunction,
and ﬁbrosis. Initial observations that intracavernous injection therapies used on a regular basis postoperatively resulted in
improvements in the return of spontaneous erectile function led to the development of penile rehabilitation protocols. Chronic
dosing of PDE-V inhibitors is now commonly used by urologists after radical prostatectomy. Despite the current enthusiasm of
penile rehabilitation therapy, current scientiﬁc evidence with clinical trials is still limited.
Copyright © 2009 M. E. Brewer Jr. and E. D. Kim. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Erectile dysfunction (ED) continues to be a signiﬁcant
complaint among men undergoing radical prostatectomy
(RP), despite meticulous nerve-sparing technique. The dis-
crepancy between preservation of the nerves and recovery
of erectile function leads us to believe that the etiology is
likely multifactorial. Smooth muscle alterations and ﬁbrotic
changes in the penis following surgery were identiﬁed as
underlying causes of penile atrophy, veno-occlusive dysfunc-
tion, and Peyronie’s-like changes. Other mechanisms, such
as penile hypoxia, are likely to contribute to post-RP erectile
dysfunction as well.
The topic of penile rehabilitation therapy (PRT) has
become an area of intense interest over the last decade. Initial
observations that intracavernous injection therapies used
on a regular basis postoperatively resulted in improvements
in the return of spontaneous erectile function led to the
development of penile rehabilitation protocols [1]. A central
question is whether vasoactive therapies, such as oral type
V phosphodiesterase (PDE-V) inhibitors and intracavernous
orintraurethralalprostadil,canlessenorreversetheeﬀectsof
causativefactorsforED.AsseveralrecentarticlesinAdvances
in Urology have thoroughly reviewed the beneﬁts of PRT, the
purpose of this article is to provide caution to the present
enthusiasm for penile rehabilitation.
2 .P e n il eI n j uryF o ll o win gR P :Bas icS c ie n c e
Thebasicsciencebehindthemechanismoferectionhasbeen
discussed previously and is beyond the scope of this review
[2]. With that said, it is important that we understand the
underlying hypothesis of penile rehabilitation therapy. In
the 1990s, it was recognized that denervation injury to the
penis aﬀects the cavernous smooth muscle. This is similar
to the skeletal muscle atrophy that is seen following spinal
cord injury. Using a rat model, Klein et al. were the ﬁrst to
demonstrate that denervation of the penis leads to apoptosis
[3]. Then in 2003, User and McVary were able to show
penile apoptosis as early as 1 day after cavernous nerve
ablation in a rat model [4]. This apoptotic process is directly
related to atrophy and ﬁbrosis. The hypothesis is that PDE-
V inhibitors promote penile rehabilitation by stimulating
smooth muscle cell replacement via a cGMP mechanism and
reducing collagen synthesis via phosphokinase G activation
[5]. By performing percutaneous penile biopsies at the time
of RP and 6 months later, Schwartz et al. were the ﬁrst
to demonstrate that early use of 100mg of sildenaﬁl after2 Advances in Urology
R Pm a yp r e s e r v ei n t r a c o r p o r e a ls m o o t hm u s c l ec o n t e n t[ 6].
Interestingly, those taking 50mg of sildenaﬁl under the same
dosing regimen showed no statistically signiﬁcant change
in smooth muscle content. There was no control group
in this study and only 21 of the enrolled 40 men were
available for follow-up. The eﬀects on the long-term return
of erectile function were not determined. Rajfer et al. from
UCLA demonstrated in several studies that rats treated with
PDE-V inhibitors had no signiﬁcant increase in the penile
shaft collagen content [5, 7, 8] .T h e s es t u d i e sh a v ep r o v i d e d
important animal model documentation of the beneﬁt of
PDE-V inhibitor therapy for the prevention of functional
and histologic changes in the penis that can occur after nerve
damage.
3. Limitationsof PresentClinicalStudies
Whiletherehavebeenmanystudiesintheratmodelshowing
the beneﬁts of local vasoactive therapies, the crossover to
clinical signiﬁcance in the human has been more diﬃcult
to prove (see Table 1). Montorsi et al. showed in 1997 that
men who performed penile injections had a superior rate
of return of adequate erections following RP than men
who did not do injections [1]. However, the study did
not include preoperative parameters of erectile function
or the use of a validated questionnaire. Also, the small
number of patients included in the study decreases its
power. Additionally, the short duration of follow-up of 12
weeks limits any conclusions regarding long-term impact of
therapy. Nevertheless, this study was the ﬁrst clinical report
to suggest a beneﬁt of a penile rehabilitation strategy using a
pharmacologic therapy.
The evidence for the use of oral agents for penile reha-
bilitation is even weaker. In 2005, Mulhall et al. reported in
a nonrandomized study that men who underwent pharma-
cologic penile rehabilitation following RP resulted in higher
rates of spontaneous functional erections [9]. Men who had
fully functional erections by self-report preoperatively were
encouraged to participate in a penile rehabilitation program
for at least 12 months following surgery. Patients who
decided to participate constituted the rehabilitation group,
while those who decided not to participate but presented for
follow-up for periodic evaluation of their erectile function
constituted the nonrehabilitation group. There were 58 men
in the rehabilitation group and 74 in the nonrehabilitation
group, but no placebo arm. This study had a strong patient
selection bias, as patients were allowed to select treatment
or observation. In addition, only men who completed 18
months of therapy were included, meaning that men who
dropped out due to lack of eﬃcacy were not part of the
analysis.
The beneﬁt induced by a PDE-V inhibitor rehabilitation
approachcomparedtoanondemandPDE-Vadministration
hasnotbeenconﬁrmed.Inafollow-uptotheirﬁrststudy[1],
Montorsi et al. prospectively studied a cohort of 80 patients
submittedtobilateralNSRRPwithadequateerectilefunction
data 12 months after surgery, as presented in their abstract
at the 2006 annual meeting of the American Urological
Association [10]. Patients were assigned to four diﬀerent
groups: no erectile therapy, intracavernosal injection of
prostaglandin E-1 on demand, PDE-V inhibitor on demand,
and PDE-V inhibitor therapy either daily or every other day
for 3 months. No signiﬁcant diﬀerence was found in the
mean IIEF score between patients treated with daily therapy
versus on demand therapy.
Bannowsky et al. from Germany reported in 2008 their
ﬁndings of low-dose sildenaﬁl for rehabilitating erectile
functionafternerve-sparingRP[11].Twenty-threemenwith
preserved erectile function based on Rigiscan testing 1-2
weekspostoperativelyreceivedsildenaﬁl25mgnightlyversus
18 men who received placebo for 52 weeks. There was a
signiﬁcant diﬀerence in IIEF-5 score and time of recovery
of erectile function between the groups (P<. 001), with
potency rates of 86% versus 66%. The authors concluded
that in cases of early penile erection, daily low-dose sildenaﬁl
leads to a signiﬁcant improvement in the recovery of erectile
function. However, the limitations to this study are that it
was performed at a single center and 95% of patients had
nocturnal erections following catheter removal, which is not
typical.
Padma-Nathan et al. performed the ﬁrst randomized,
placebo-controlled trial of chronic PDE-V inhibitor therapy
for the purposes of penile rehabilitation and presented their
ﬁndings at the 2003 American Urological Association annual
meeting [12]. They concluded that nightly administration
of sildenaﬁl for 9 months following nerve-sparing radical
retropubic prostatectomy (NSRRP) increased the return of
spontaneouserectionscomparedwithplacebo.However,this
study has been criticized for the seemingly low percentage
(4%) of men considered responders in the placebo arm.
Additionally, the criteria for being considered a responder
were stringent, as responders were deﬁned as those having
a combined score of >8f o rI I E FQ 3a n d4a n dp o s i t i v e
response to the question “Over the past 4 weeks, have your
erections been good enough for satisfactory sexual activity?”
[13] The ﬁndings of this study were recently published in the
International Journal of Impotence Research [14].
A subset of these men had nocturnal penile tumescence
and rigidity (NPTR) testing performed preoperatively and at
various time points postoperatively [15]. The authors con-
cluded that nightly sildenaﬁl objectively improved nocturnal
erections versus placebo.
The limitation of this studyis thatwhilebeing suggestive,
nocturnal tumescence data interpretation does not necessar-
ily correlate with return of clinically usable erections.
In contrast, in the largest randomized, double-blind,
double-dummy, multicenter, parallel study done to date,
Montorsi et al. recently reported on a vardenaﬁl trial after
bilateral nerve-sparing RP [16]. A total of 628 men were
randomized to placebo, nightly vardenaﬁl, or on demand
vardenaﬁl for 9 months, followed by a 2-month washout
period, and an optional 2-month open-label period. The
results clearly show that nightly dosing with vardenaﬁl did
not have any eﬀe c tb e y o n dt h a to fo nd e m a n du s e .F o l l o wi n g
washout,IIEF-EF scores ≥22 wereachievedin 28.9%, 24.1%,
and 29.1% of patients for placebo, vardenaﬁl nightly, and
vardenaﬁl on demand groups, respectively, showing no
statistically signiﬁcant diﬀerence among the groups. MeanAdvances in Urology 3
Table 1: Review of clinical studies.
Authors n (number of patients) Conclusions and limitations
Montorsi et al. (1997) 30
Alprostadil injections led to superior rate of
return of adequate erections; no preoperative EF
parameters, no questionnaire, small number of
patients, short follow-up
Mulhall et al. (2005) 132
Pharmacologic penile rehabilitation protocol
results in higher rates of spontaneous erections
and erectogenic drug response; no placebo arm,
strong patient selection bias, dropouts were not
included
Montorsi et al. (2006) 80
No signiﬁcant diﬀerence is IIEF scores of patients
using on demand versus daily PDE5 inhibitors
post-NSRRP; compliance not reported
Bannowsky et al. (2008) 43
Daily low-dose sildenaﬁl leads to improved
recovery of EF post-NSRRP (86% versus 66%
placebo); small number of patients, not
placebo-controlled, single center, only included
patients who showed preserved EF post-operative
with Rigiscan testing
Padma-Nathan et al. (2008) 76
First placebo-controlled trial suggesting beneﬁt of
daily PDE5 inhibitor use: nightly sildenaﬁl
increased return of spontaneous erections; low
percentage (4%) considered responders in placebo
arm, but strict deﬁnition of responders
McCullough et al. (2008) 54
Nightly sildenaﬁl improved nocturnal erections
versus placebo; nocturnal tumescence data do not
necessarily correlate with clinically usable erections
Montorsi et al. (2008) 628 Nightly vardenaﬁl did not have any eﬀect beyond
that of on demand use
per-patient success rates for intercourse completion were
not signiﬁcantly diﬀerent among treatment groups either.
While on demand dosing was eﬃcacious, nightly vardenaﬁl
for the purpose of penile rehabilitation was not eﬃcacious.
This well-designed study provides a cautionary note for
the present enthusiasm of oral PDE-V inhibitors for penile
rehabilitation therapy. The authors concluded that: “the
ﬁndingthatondemanddosingismoreeﬀectiveinimproving
both erectile function and sexual intercourse completion
rates within this patient population prompts reconsideration
of the current practice of prescribing nightly PDE5 inhibitor
therapy, as on demand use of vardenaﬁl if equally eﬀective in
men with ED following NSRP.”
Point-counterpoint debates have become common
regarding the eﬃcacy of penile rehabilitation following RP.
In one such example, Abraham Morgentaler from Harvard
University listed several intriguing arguments [17]. First,
he questioned the theory that penile rehabilitation helps
to reverse the chronic hypoxia and ischemia of the ﬂaccid
penis following RP. “But why is there reason to suspect that
the ﬂaccid penis is hypoxic, despite having venous oxygen
tension? After all, the endothelium of all venous structures
suﬀers no ill eﬀects despite a lifetime of exposure to oxygen
levelsthatarewellbelowthoseseeninarterialblood.Second,
there is no reason to believe that the penis is ischemic
following RP. If it were ischemic, would it not eventually
become necrotic? Furthermore, PDE-V inhibitors do not
increase blood ﬂow to the ﬂaccid penis, so how can beneﬁt
occur?”
Similarly, in a more recent point-counterpoint debate
at the 2008 AUA Annual Meeting in Orlando, Fla, Craig
DonatuccifromDukeUniversitywaschargedwithproviding
the contrary argument as whether penile rehabilitation was
eﬀective after RP. He presented many of the same points
listed above, describing the pitfalls of the clinical trials that
have been presented thus far. He stated: “There is not yet
enoughevidencetodeclarepenilerehabilitationeﬀective;but
Iamnotsuﬃcientlyconvincedoftheineﬀectivenessofpenile
rehabilitation to recommend against it. My opinion is that
the beneﬁts of penile rehabilitation are “not proven”; yet it is
currently the standard of care” [18].
4. Conclusions
Thestudyofpenilerehabilitationisinactiveevolution.There
areintriguingdatasupportingtheuseofpenilerehabilitation
in the animal model, but these studies may not translate into
human eﬀect. While many published reports of clinical trials
point toward improved outcomes with active treatment,
these studies have signiﬁcant limitations. Most recently,
the only large, randomized, placebo-controlled trial to date
showed no clear beneﬁt of rehabilitation with vardenaﬁl
versus on demand dosing. In fact, quite the opposite was
shown. Clearly, more randomized, placebo-controlled trials4 Advances in Urology
are needed. Unfortunately, these present many challenges.
First, these trials prove costly with poor long-term compli-
ance and signiﬁcant early dropout rates. Second, it cannot be
overlooked that diﬀerences in nerve-sparing technique and
outcomes between surgeons can confound interpretation of
results. Even though the beneﬁts of penile rehabilitation
are still questionable, the practice of frequent and chronic
administration of PDE-V inhibitors has become standard
of care for many urologists. We suggest proceeding with
caution when encouraging our patients to adhere to a
rehabilitation regimen, until more deﬁnitive results are
available.
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